APONTIS PHARMA AG (APPH.DE) Stock Fundamental Analysis
Europe - FRA:APPH - DE000A3CMGM5 - Common Stock
10.9 EUR
+0.15 (+1.4%)
Taking everything into account, APPH scores 5 out of 10 in our fundamental rating. APPH was compared to 54 industry peers in the Pharmaceuticals industry. While APPH has a great health rating, there are worries on its profitability. APPH has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year APPH was profitable.
In the past year APPH has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: APPH reported negative net income in multiple years.
In multiple years APPH reported negative operating cash flow during the last 5 years.
1.2 Ratios
APPH's Return On Assets of 1.71% is on the low side compared to the rest of the industry. APPH is outperformed by 61.11% of its industry peers.
APPH has a worse Return On Equity (2.38%) than 61.11% of its industry peers.
The Return On Invested Capital of APPH (2.02%) is worse than 62.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.71% | ||
| ROE | 2.38% | ||
| ROIC | 2.02% |
ROA(3y)-4.49%
ROA(5y)-3.77%
ROE(3y)-9.48%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 1.55%, APPH is in line with its industry, outperforming 40.74% of the companies in the same industry.
Looking at the Operating Margin, with a value of 2.61%, APPH is doing worse than 62.96% of the companies in the same industry.
In the last couple of years the Operating Margin of APPH has declined.
The Gross Margin of APPH (57.16%) is worse than 66.67% of its industry peers.
APPH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.61% | ||
| PM (TTM) | 1.55% | ||
| GM | 57.16% |
OM growth 3Y-32.75%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), APPH is destroying value.
The number of shares outstanding for APPH remains at a similar level compared to 1 year ago.
The number of shares outstanding for APPH has been reduced compared to 5 years ago.
APPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
APPH has an Altman-Z score of 5.82. This indicates that APPH is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.82, APPH belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
APPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.82 |
ROIC/WACC0.28
WACC7.19%
2.3 Liquidity
A Current Ratio of 6.82 indicates that APPH has no problem at all paying its short term obligations.
With an excellent Current ratio value of 6.82, APPH belongs to the best of the industry, outperforming 98.15% of the companies in the same industry.
A Quick Ratio of 4.86 indicates that APPH has no problem at all paying its short term obligations.
APPH has a Quick ratio of 4.86. This is amongst the best in the industry. APPH outperforms 98.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.82 | ||
| Quick Ratio | 4.86 |
3. Growth
3.1 Past
APPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 106.67%, which is quite impressive.
APPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.12%.
Measured over the past years, APPH shows a small growth in Revenue. The Revenue has been growing by 3.89% on average per year.
EPS 1Y (TTM)106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.25%
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%14.55%
3.2 Future
Based on estimates for the next years, APPH will show a very strong growth in Earnings Per Share. The EPS will grow by 128.83% on average per year.
APPH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.31% yearly.
EPS Next Y393.69%
EPS Next 2Y194.54%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue Next Year21.53%
Revenue Next 2Y20.18%
Revenue Next 3Y18.69%
Revenue Next 5Y15.31%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 121.11 indicates a quite expensive valuation of APPH.
Compared to the rest of the industry, the Price/Earnings ratio of APPH indicates a slightly more expensive valuation: APPH is more expensive than 66.67% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.06. APPH is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 11.10 indicates a reasonable valuation of APPH.
APPH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. APPH is cheaper than 75.93% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 32.73. APPH is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 121.11 | ||
| Fwd PE | 11.1 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, APPH is valued a bit more expensive than the industry average as 64.81% of the companies are valued more cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 30.32 |
4.3 Compensation for Growth
APPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as APPH's earnings are expected to grow with 128.83% in the coming years.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y194.54%
EPS Next 3Y128.83%
5. Dividend
5.1 Amount
APPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:APPH (11/7/2025, 7:00:00 PM)
10.9
+0.15 (+1.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners38.49%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap92.65M
Revenue(TTM)48.47M
Net Income(TTM)753.60K
Analysts82.86
Price Target13.77 (26.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)35%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)26.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 121.11 | ||
| Fwd PE | 11.1 | ||
| P/S | 1.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.93 | ||
| P/tB | 7.39 | ||
| EV/EBITDA | 30.32 |
EPS(TTM)0.09
EY0.83%
EPS(NY)0.98
Fwd EY9.01%
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS5.7
BVpS3.72
TBVpS1.48
PEG (NY)0.31
PEG (5Y)N/A
Graham Number2.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.71% | ||
| ROE | 2.38% | ||
| ROCE | 3.09% | ||
| ROIC | 2.02% | ||
| ROICexc | 2.02% | ||
| ROICexgc | 3.79% | ||
| OM | 2.61% | ||
| PM (TTM) | 1.55% | ||
| GM | 57.16% | ||
| FCFM | N/A |
ROA(3y)-4.49%
ROA(5y)-3.77%
ROE(3y)-9.48%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-34.78%
ROICexgc growth 5YN/A
ROICexc growth 3Y-37.05%
ROICexc growth 5YN/A
OM growth 3Y-32.75%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
F-Score5
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 214.22% | ||
| Cap/Sales | 7.92% | ||
| Interest Coverage | 9.42 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.82 | ||
| Quick Ratio | 4.86 | ||
| Altman-Z | 5.82 |
F-Score5
WACC7.19%
ROIC/WACC0.28
Cap/Depr(3y)153.41%
Cap/Depr(5y)119.86%
Cap/Sales(3y)6.51%
Cap/Sales(5y)4.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.25%
EPS Next Y393.69%
EPS Next 2Y194.54%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%14.55%
Revenue Next Year21.53%
Revenue Next 2Y20.18%
Revenue Next 3Y18.69%
Revenue Next 5Y15.31%
EBIT growth 1Y113.23%
EBIT growth 3Y-33.96%
EBIT growth 5YN/A
EBIT Next Year419.89%
EBIT Next 3Y131.3%
EBIT Next 5YN/A
FCF growth 1Y16.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.46%
OCF growth 3YN/A
OCF growth 5YN/A
APONTIS PHARMA AG / APPH.DE FAQ
Can you provide the ChartMill fundamental rating for APONTIS PHARMA AG?
ChartMill assigns a fundamental rating of 5 / 10 to APPH.DE.
What is the valuation status of APONTIS PHARMA AG (APPH.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to APONTIS PHARMA AG (APPH.DE). This can be considered as Fairly Valued.
What is the profitability of APPH stock?
APONTIS PHARMA AG (APPH.DE) has a profitability rating of 1 / 10.
How financially healthy is APONTIS PHARMA AG?
The financial health rating of APONTIS PHARMA AG (APPH.DE) is 9 / 10.
What is the earnings growth outlook for APONTIS PHARMA AG?
The Earnings per Share (EPS) of APONTIS PHARMA AG (APPH.DE) is expected to grow by 393.69% in the next year.